CK 0807
Alternative Names: CK-0807Latest Information Update: 21 Jul 2021
At a glance
- Originator Cellenkos
- Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Regulatory T-lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical T-cell lymphoma
Most Recent Events
- 06 Jul 2021 Preclinical trials in T-cell lymphoma in USA (Parenteral) before July 2021 (Cellenkos pipeline, July 2021)
- 06 Jul 2021 Cellenkos plans to initiate IND-enabling development for T-cell lymphoma in 2021 (Cellenkos pipeline, July 2021)
- 01 Apr 2021 Cellenkos publishes PCT application on mbilical cord blood-derived regulatory T cells for protection worldwide